Zur Wieksonikeit von AURIZON bei ukuter und chronischer Otitis externa (Hund) unter besonderer Berucksichtigung der antimikrobiellen Aktivitat von MarbofloxacinThe efficacy of AURIZON((R)) in acute and chronic otitis externa (dogs) taking into accoun

摘要

Marbofloxacin (fluoroquinolone) and clotrimazole (imidazole derivative) are substances contained in AURIZON(R) (MA number: 400518.00.00, Vetoquinol GmbH, 88212 Ravensburg). In comparison to other topically applied otitis antibiotics (gentamicin, polymyxin B, fusidic acid, enrofloxacin), marbofloxacin can for the most part claim superior in-vitro efficacy. It outnumbers other antibiotics, particularly with regard to Ps. aeruginosa, a highly resistant and dreaded pathogen in otitis externa. Above that, in-vitro susceptibility rates for that germ between 74% - recordable for up to eight years (1994-2001), demonstrate that currently there is no worsening of the situation of resistance (Vetoquinol Resistance-Monitoring-Programme). Clinical efficacy of AURIZON(R) in acute and sub-acute otitis externa was the subject of afield study of which the results are presented here. A total of 362 dogs, either suffering from otitis externa erythematosa et ceruminosa (OEec) or Otitis externa purulenta (OEp), were treated with AURIZON(R) over a period of 7 or 14 days, respectively. Success rates (= clinical cure or marked improvement) of at least 90% could be attained in both treatment groups. Furthermore, 65%-75% of all pre-treated otitis cases were also healed (= clinical cure) by the AURIZON(R) treatment. Acting bactericidal and possessing specific physiochemical properties, marbofloxacin reaches a high cutaneous penetration, whilst accumulating in macrophages. Topical and concurrent systemic application of marbofloxacin thus offers an auspicious treatment Option in the case of grave otitis externa caused by gram-negative germs, and/or where the middle ear has been affected (otitis media). Convincing results were presented when examining this treatment option. Clinical cure could be achieved in more than 80% of cases of chronic otitis externa (n=38 dogs) on day 28, i.e. 7 days following completion of MARBOCYL(R) application, using a combination of AURIZON(R) (14 days, taken once daily), and MARBOCYL(R) (maximum of 21 days, 5 mg/kg/24 h, oral). At 4% the relapse rate was very low. The 5 mg/kg/24 h experimental dosage of MARBOCYL(R) applied in this trial is not authorised in Germany. However, according to published data the outlined dosage has been proven save and clinically effective in the treatment of Ps. aeruginosa-dominated dermatitis and otitis.